CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 277 filers reported holding CRISPR THERAPEUTICS AG in Q2 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $207,000 | -31.0% | 3,292 | -16.8% | 0.01% | -33.3% |
| Q4 2021 | $300,000 | -18.7% | 3,957 | +20.1% | 0.02% | -25.0% |
| Q3 2021 | $369,000 | -14.0% | 3,295 | +3.1% | 0.03% | -17.6% |
| Q2 2021 | $429,000 | +57.7% | 3,197 | +43.4% | 0.03% | +36.0% |
| Q1 2021 | $272,000 | -49.3% | 2,230 | -36.4% | 0.02% | -50.0% |
| Q4 2020 | $537,000 | +85.2% | 3,507 | +1.2% | 0.05% | +51.5% |
| Q3 2020 | $290,000 | +14.6% | 3,466 | +0.6% | 0.03% | -2.9% |
| Q2 2020 | $253,000 | – | 3,445 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |